Furthermore, there was no proliferation-inhibitory effect observed in human normal CD34+ hematopoietic cells from 5 independent donors in the presence of SR140333 (Fig. 3E) or Aprepitant (Fig. 3F) and no hemolytic toxicity in human red blood cells (SI Appendix, Fig. S4B), indicating selective targeting of tumor cells by NK-1R antagonists. Here, TACR1 is linked to neoplasm.